A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes (2022)
Attributed to:
University of Oxford – Confidence in Concept 2019
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00277-022-04853-4
PubMed Identifier: 35488900
Publication URI: http://europepmc.org/abstract/MED/35488900
Type: Journal Article/Review
Parent Publication: Annals of Hematology
Issue: 8
ISSN: 0939-5555